Alterity Therapeutics received official FDA minutes confirming the design and pathway for a pivotal Phase 3 trial of ATH434, a drug candidate for Multiple System Atrophy (MSA). The FDA agreed that a single Phase 3 trial, supported by previous Phase 2 data, could be sufficient for approval. The trial will enroll about 200 patients treated with ATH434 or placebo for 12 months, with key efficacy and safety endpoints agreed upon. Alterity plans to start the Phase 3 trial by the end of 2026, aiming to provide a new treatment option for this rare, progressive neurodegenerative disease with no current cure.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
